Cara Therapeutics, Inc. (CARA) News
Filter CARA News Items
CARA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CARA News Highlights
- CARA's 30 day story count now stands at 3.
- Over the past 20 days, the trend for CARA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- CONN are the most mentioned tickers in articles about CARA.
Latest CARA News From Around the Web
Below are the latest news stories about CARA THERAPEUTICS INC that investors may wish to consider to help them evaluate CARA as an investment opportunity.
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsApproval triggers $1.5 million milestone payment to CaraSTAMFORD, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. received manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for KORSUVA® IV Injection Syringe for the |
Companies Like Cara Therapeutics (NASDAQ:CARA) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSTAMFORD, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY. A webcast of the presentation can be accessed unde |
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call TranscriptCara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript August 7, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.00058 EPS, expectations were $0.56. Operator: Thank you for standing by, and welcome to Cara Therapeutics’ Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. […] |
Q2 2023 Cara Therapeutics Inc Earnings CallQ2 2023 Cara Therapeutics Inc Earnings Call |
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue EstimatesCara (CARA) delivered earnings and revenue surprises of -3.57% and 6.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Cara Therapeutics Reports Second Quarter 2023 Financial Results– 2Q23 total revenue of $6.9M including collaborative revenue of $5.4M from the Company’s share of profit of KORSUVA® (difelikefalin) injection – – Demand for KORSUVA injection accelerating with 46% increase in vial orders quarter to quarter – – 2024 ESRD PPS proposed rule suggests additional funding for TDAPA-designated products in existing functional category; final rule expected in 4Q23 – – Three late-stage oral difelikefalin clinical programs tracking to plan; Internal readout of Part A of K |
Cara Therapeutics Appoints Helen M. Boudreau to Board of DirectorsSTAMFORD, Conn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Helen M. Boudreau to its Board of Directors. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous |
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceSTAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:00 a.m. EDT in Boston, MA. A webcast of the presentation can be accessed under "Events & P |
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023STAMFORD, Conn., July 24, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 7, 2023, at 4:30 p.m. ET to report second quarter 2023 financial results and provide a corporate update. To participate in the conference call, please register here. Registrant |